A detailed history of Profund Advisors LLC transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Profund Advisors LLC holds 27,635 shares of DAWN stock, worth $243,188. This represents 0.01% of its overall portfolio holdings.

Number of Shares
27,635
Previous 20,950 31.91%
Holding current value
$243,188
Previous $136,000 42.65%
% of portfolio
0.01%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 05, 2025

BUY
$5.8 - $7.59 $38,773 - $50,739
6,685 Added 31.91%
27,635 $194,000
Q2 2025

Aug 07, 2025

SELL
$6.16 - $7.97 $22,502 - $29,114
-3,653 Reduced 14.85%
20,950 $136,000
Q1 2025

May 08, 2025

SELL
$7.93 - $13.21 $46,160 - $76,895
-5,821 Reduced 19.13%
24,603 $195,000
Q4 2024

Feb 13, 2025

BUY
$12.46 - $16.39 $44,021 - $57,905
3,533 Added 13.14%
30,424 $385,000
Q3 2024

Nov 13, 2024

SELL
$12.72 - $16.03 $9,107 - $11,477
-716 Reduced 2.59%
26,891 $374,000
Q2 2024

Aug 13, 2024

SELL
$12.03 - $17.69 $36,150 - $53,158
-3,005 Reduced 9.82%
27,607 $380,000
Q1 2024

May 08, 2024

SELL
$13.56 - $17.46 $111,259 - $143,259
-8,205 Reduced 21.14%
30,612 $505,000
Q4 2023

Feb 14, 2024

SELL
$9.68 - $15.37 $13,823 - $21,948
-1,428 Reduced 3.55%
38,817 $566,000
Q3 2023

Nov 13, 2023

SELL
$11.22 - $14.86 $138,982 - $184,070
-12,387 Reduced 23.54%
40,245 $493,000
Q2 2023

Aug 10, 2023

BUY
$11.74 - $14.47 $203,137 - $250,374
17,303 Added 48.98%
52,632 $628,000
Q1 2023

May 11, 2023

BUY
$12.75 - $23.41 $450,444 - $827,051
35,329 New
35,329 $472,000

Others Institutions Holding DAWN

About Day One Biopharmaceuticals, Inc.


  • Ticker DAWN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 73,461,104
  • Market Cap $646M
  • Description
  • Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...
More about DAWN
Track This Portfolio

Track Profund Advisors LLC Portfolio

Follow Profund Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Profund Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Profund Advisors LLC with notifications on news.